North America Offsite Sterilisation Service Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

North America Offsite Sterilisation Service Market Overview

The North America offsite sterilisation service market was valued at USD 1.33 billion in 2025 and is projected to reach USD 2.18 billion by 2033, growing at a CAGR of 6.4% from 2026 to 2033. The market is witnessing steady growth driven by increasing demand for sterile medical devices, rising healthcare expenditures, and stringent regulatory requirements governing infection prevention and product safety across the healthcare and life sciences sectors.

The growing volume of surgical procedures, expanding medical device manufacturing activities, and increasing adoption of single-use healthcare products are encouraging healthcare providers and manufacturers to rely on specialized offsite sterilisation services. Ethylene oxide (EtO), gamma irradiation, electron beam (E-beam), and X-ray sterilisation technologies continue to play a critical role in ensuring product sterility while supporting large-scale processing needs. In addition, investments in sterilisation capacity expansion, compliance with evolving regulatory standards, and the rising demand for contract sterilisation services from pharmaceutical, biotechnology, and medical device companies are further contributing to market growth across North America.

Key Market Trends & Insights

• The United States dominated the North America offsite sterilisation service market, accounting for 84.6% of the regional revenue share in 2025, supported by its extensive healthcare infrastructure, large medical device manufacturing sector, and stringent sterilisation regulations.
• The Ethylene Oxide Sterilisation segment led the market with a 44.8% share in 2025, driven by its extensive compatibility with heat- and moisture-sensitive medical devices and complex healthcare products
• Canada is expected to be the fastest-growing country market, projected to register a CAGR of 7.1% from 2026 to 2033, supported by expanding healthcare investments, increasing medical device production activities, growing demand for outsourced sterilisation services, and ongoing modernization of healthcare facilities.
• Electron Beam Sterilisation are the fastest-growing service technology type, projected to register a CAGR of 7.4%, reflecting the surge in demand for faster and environmentally efficient sterilisation solutions.
• The Medical Devices segment dominated the product type category with a 57.6% revenue share in 2025, led by rising production volumes of disposable and reusable medical products.
• Medical Device Sterilisation accounted for 49.3% of the market, preferred by the substantial volume of medical devices requiring sterilisation before use.
• The Pharmaceutical Sterilisation segment is the fastest-growing application category, with a CAGR of 7.0%, driven by increasing pharmaceutical manufacturing and biologics production activities.

Market Size & Forecast

• Global Market Value (2025): USD 1.33 Billion
• Expected Market Value (2033): USD 2.18 Billion
• Forecast CAGR (2026–2033): 6.4%
• Leading Country in 2025: United States
• Fastest Growing Country: Canada

Report Scope and North America Offsite Sterilisation Service Market Segmentation

North America Offsite Sterilisation Service Market Trends

Trend: Rising Outsourcing of Sterilisation Services by Medical Device Manufacturers

Medical device manufacturers across North America are increasingly outsourcing sterilisation processes to specialized service providers to improve operational efficiency, ensure regulatory compliance, and reduce capital expenditures associated with in-house sterilisation infrastructure. Growing production volumes of single-use medical devices, implants, surgical instruments, and diagnostic products are driving demand for scalable contract sterilisation solutions. Service providers are expanding ethylene oxide (EtO), gamma irradiation, electron beam, and X-ray sterilisation capabilities to accommodate evolving customer requirements while maintaining validated, high-throughput processing environments.

For instance, in September 2024, STERIS announced the expansion of its contract sterilisation processing capabilities in North America to support growing demand from medical device manufacturers and healthcare product companies.

North America Offsite Sterilisation Service Market Dynamics

Key Market Driver: Increasing Demand for Sterile Medical Devices and Healthcare Products

The growing volume of surgical procedures, expanding healthcare services, and increasing utilization of disposable medical products are creating substantial demand for offsite sterilisation services throughout North America. Medical device manufacturers, pharmaceutical companies, and healthcare providers rely on specialized sterilisation partners to ensure product safety, regulatory compliance, and uninterrupted supply chain operations. Rising infection prevention requirements and stricter quality standards are further accelerating adoption of outsourced sterilisation services across the region.

For instance, in May 2024, Sotera Health reported continued investment in sterilisation service capacity to support increasing customer demand from the medical device and pharmaceutical sectors across North America.

Key Restraint/Challenge: Regulatory Scrutiny and Environmental Compliance Requirements

A significant restraint in the North America offsite sterilisation service market is the increasing regulatory scrutiny surrounding sterilisation emissions, particularly ethylene oxide processing facilities. Service providers must comply with evolving environmental regulations, emission control standards, permitting requirements, and facility modernization initiatives, which can increase operational costs and delay expansion projects. Compliance investments, monitoring obligations, and community concerns regarding sterilisation facilities continue to create challenges for market participants seeking capacity growth.

For instance, in March 2024, the United States Environmental Protection Agency finalized stricter emissions standards for commercial sterilisation facilities utilizing ethylene oxide, requiring operators to implement additional emissions-control measures.

Key Market Opportunity: Expansion of Alternative Sterilisation Technologies

The growing adoption of alternative sterilisation technologies presents a significant market opportunity. Increasing demand for gamma irradiation, electron beam, and X-ray sterilisation is encouraging service providers to diversify processing capabilities and reduce dependence on traditional sterilisation methods. Advancements in radiation-based sterilisation systems, combined with rising demand from medical device, biotechnology, and pharmaceutical manufacturers, are creating new growth opportunities across North America while supporting greater operational flexibility and capacity expansion.

For instance, in June 2024, STERIGENICS continued investments in radiation sterilisation infrastructure to meet increasing customer demand for alternative sterilisation solutions across the healthcare and life sciences industries.

North America Offsite Sterilisation Service Market Scope

The North America offsite sterilisation service market is segmented on the basis of service technology, product type, application, and end user.

• By Service Technology

On the basis of service technology, the North America offsite sterilisation service market is segmented into Ethylene Oxide Sterilisation, Gamma Sterilisation, Electron Beam Sterilisation, Steam Sterilisation, NO2 Sterilisation, and Others. The Ethylene Oxide (EtO) Sterilisation segment dominated the market with a 44.8% share in 2025, owing to its extensive compatibility with heat- and moisture-sensitive medical devices and complex healthcare products. EtO sterilisation is widely used for catheters, implants, surgical kits, and diagnostic devices that cannot withstand conventional sterilisation methods. The technology offers deep penetration capabilities and high sterilisation effectiveness across diverse materials and packaging formats. Medical device manufacturers continue to rely on EtO services due to established regulatory acceptance and large-scale processing capacity. Contract sterilisation providers maintain significant investments in EtO infrastructure to support growing healthcare demand. Its broad applicability and proven performance continue to reinforce its leadership position across North America.

The Electron Beam Sterilisation segment is projected to witness the fastest growth at a CAGR of 7.4% from 2026 to 2033, driven by increasing demand for faster and environmentally efficient sterilisation solutions. E-beam technology offers shorter processing times and eliminates the need for radioactive materials or chemical sterilants. Growing concerns regarding emissions regulations and operational efficiency are encouraging healthcare manufacturers to evaluate alternative sterilisation methods. The technology is increasingly being adopted for pharmaceuticals, medical packaging, and disposable healthcare products. Continuous advancements in accelerator systems are improving processing flexibility and throughput capacity. Rising investments in radiation-based sterilisation facilities are expected to further support segment growth throughout the forecast period.

• By Product Type

On the basis of product type, the North America offsite sterilisation service market is segmented into medical devices, surgical instruments, pharmaceutical products, biopharmaceutical products, laboratory equipment, healthcare consumables, and others. The Medical Devices segment accounted for the largest market share of 57.6% in 2025, driven by rising production volumes of disposable and reusable medical products. Products such as catheters, syringes, implants, infusion systems, and diagnostic equipment require validated sterilisation before commercial distribution. Growing demand for infection prevention and patient safety is supporting sterilisation service adoption among device manufacturers. Regulatory authorities maintain strict sterility standards, further increasing reliance on specialized offsite providers. The expansion of minimally invasive procedures is also contributing to higher medical device consumption. Strong manufacturing activity across the United States and Canada continues to sustain segment dominance.

The Biopharmaceutical Products segment is anticipated to register the fastest growth at a CAGR of 7.2% from 2026 to 2033, supported by increasing investments in biologics, cell therapies, and advanced pharmaceutical manufacturing. Biopharmaceutical products require highly controlled sterilisation and contamination management processes to ensure product integrity. Rising research activities and growing commercialization of biologic drugs are creating new sterilisation requirements. Manufacturers are increasingly outsourcing sterilisation activities to specialized providers with advanced capabilities. The growth of personalized medicine and innovative therapeutic platforms is further expanding demand. Increasing regulatory emphasis on sterility assurance is expected to accelerate segment expansion across North America.

• By Application

On the basis of application, the North America offsite sterilisation service market is segmented into medical device sterilisation, pharmaceutical sterilisation, surgical equipment sterilisation, packaging sterilisation, laboratory material sterilisation, and others. The Medical Device Sterilisation segment dominated the market with a 49.3% share in 2025, owing to the substantial volume of medical devices requiring sterilisation before use. Healthcare facilities and regulatory agencies demand stringent sterility standards for all patient-contact devices. The growing prevalence of chronic diseases and increasing surgical procedures are driving medical device utilization. Manufacturers are increasingly outsourcing sterilisation operations to ensure compliance and operational efficiency. Advanced sterilisation technologies enable large-scale processing while maintaining product quality. The segment continues to benefit from expanding healthcare infrastructure and medical technology innovation.

The Pharmaceutical Sterilisation segment is expected to witness the fastest growth at a CAGR of 7.0% from 2026 to 2033, driven by increasing pharmaceutical manufacturing and biologics production activities. Pharmaceutical companies require validated sterilisation processes for drug products, packaging materials, and production components. Rising demand for injectable therapies and sterile pharmaceutical formulations is supporting market growth. Outsourcing sterilisation services allows manufacturers to focus on core production operations while maintaining compliance. Growing investments in pharmaceutical research and manufacturing facilities are creating additional opportunities. Expanding regulatory requirements for product safety and quality assurance are further accelerating segment adoption.

• By End User

On the basis of end user, the North America offsite sterilisation service market is segmented into hospitals, clinics, medical device companies, pharmaceutical companies, food & beverage companies, academic & research institutes, and others. The Medical Device Companies segment held the largest market share of 38.7% in 2025, supported by increasing outsourcing of sterilisation activities to specialized service providers. These companies require reliable, scalable, and compliant sterilisation solutions for a broad range of healthcare products. Rising production volumes and growing product complexity are driving demand for advanced sterilisation technologies. Offsite service providers help manufacturers reduce infrastructure costs and improve operational flexibility. Regulatory compliance requirements also encourage partnerships with experienced sterilisation specialists. The continued expansion of the medical device industry is reinforcing the segment’s dominant position.

The Pharmaceutical Companies segment is projected to be the fastest-growing end-user category at a CAGR of 7.3% from 2026 to 2033, driven by expanding drug manufacturing, biologics development, and sterile product production. Pharmaceutical firms increasingly utilize contract sterilisation services to meet stringent regulatory standards and quality requirements. The rise of injectable medicines and advanced therapies is creating greater demand for sterilised packaging and production materials. Outsourcing provides cost advantages and access to specialized sterilisation expertise. Growing investments in pharmaceutical innovation across North America are supporting market expansion. The increasing focus on contamination control and product safety is expected to sustain strong growth in this segment.

North America Offsite Sterilisation Service Market Regional Analysis

The United States dominated the North America offsite sterilisation service market, accounting for 84.6% of the regional revenue share in 2025, supported by its extensive healthcare infrastructure, large medical device manufacturing sector, and stringent sterilisation regulations. The country benefits from extensive adoption of outsourced sterilisation services across hospitals, contract manufacturing organizations, and life sciences companies, driven by rising demand for sterile medical devices and single-use healthcare products. The presence of large-scale contract sterilisation providers, along with continuous investments in ethylene oxide, gamma irradiation, and electron beam infrastructure, further strengthens market leadership. Increasing surgical procedures, expanding biologics production, and strong focus on regulatory compliance and patient safety continue to reinforce the United States’ dominant position in the regional market.

U.S. Offsite Sterilisation Service Market Insight

The U.S. offsite sterilisation service market is witnessing strong growth due to rising demand for sterile medical devices, increasing surgical volumes, and stringent FDA regulatory standards for infection control and product safety. The country’s advanced healthcare infrastructure, along with the strong presence of leading medical device and pharmaceutical manufacturers, is driving large-scale adoption of outsourced sterilisation services. Growing reliance on ethylene oxide, gamma irradiation, and electron beam sterilisation technologies is further supporting market expansion. In addition, increasing biologics production and expanding use of single-use medical products are accelerating demand across contract sterilisation providers.

Canada Offsite Sterilisation Service Market Insight

The Canada offsite sterilisation service market is experiencing steady growth, supported by expanding healthcare investments, rising medical device imports and manufacturing activities, and increasing adoption of outsourced sterilisation solutions. The country’s strong focus on infection prevention standards and regulatory alignment with global sterilisation protocols is encouraging wider service adoption. Hospitals, pharmaceutical firms, and device manufacturers are increasingly relying on external sterilisation providers to improve efficiency and compliance. In addition, rising demand for advanced healthcare consumables and growing biotechnology activities are contributing to sustained market expansion.

Mexico Offsite Sterilisation Service Market Insight

The Mexico offsite sterilisation service market is witnessing gradual but steady growth, driven by expanding healthcare infrastructure, increasing medical device manufacturing, and rising demand for cost-effective sterilisation solutions. The country benefits from its growing role as a medical device production hub, with strong export-oriented manufacturing supporting sterilisation service demand. Increasing awareness of infection control standards and gradual regulatory strengthening are encouraging outsourcing of sterilisation processes. In addition, rising pharmaceutical production and expanding hospital networks are further supporting market development across the country.

North America Offsite Sterilisation Service Market Share

The North America offsite sterilisation service industry is primarily led by well-established companies, including:

• STERIS plc (U.S.)
• Sotera Health (U.S.)
• Sterigenics (U.S.)
• Nelson Labs (U.S.)
• E-BEAM Services, Inc. (U.S.)
• Cosmed Group, Inc. (U.S.)
• Andersen Sterilizers (U.S.)
• BeamOne LLC (U.S.)
• Life Science Outsourcing, Inc. (U.S.)
• Nordion (Canada)
• SteriPro Canada (Canada)
• Sterilucent Canada (Canada)
• Getinge AB (Sweden)
• Cardinal Health (U.S.)
• Medline Industries, LP (U.S.)
• Stryker (U.S.)
• Boston Scientific (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• BD (U.S.)

Latest Developments in North America Offsite Sterilisation Service Market

• In April 2024, the U.S. Environmental Protection Agency (EPA) finalized stricter emission standards for commercial ethylene oxide sterilisation facilities, introducing enhanced emission controls, continuous monitoring requirements, and stricter reporting obligations. This regulatory update significantly impacted offsite sterilisation service providers operating EtO-based facilities, requiring investments in upgraded environmental control technologies and facility modernization
• In October 2023, Sterigenics, a Sotera Health company, expanded its gamma irradiation and electron beam sterilisation services across multiple North American facilities in response to increasing demand for alternative sterilisation methods. The expansion improved processing efficiency, capacity, and flexibility for medical devices, pharmaceuticals, and healthcare consumables, while also supporting manufacturers seeking diversified sterilisation pathways for complex product portfolios
• In July 2022, Sotera Health, through its subsidiaries Sterigenics and Nelson Labs, announced expansion initiatives to increase sterilisation capacity across North America, focusing on ethylene oxide (EtO) and radiation-based sterilisation systems. These investments were driven by rising demand from medical device and pharmaceutical manufacturers and aimed at improving throughput, reducing processing delays, and strengthening supply chain reliability for critical healthcare products
• In March 2022, Becton Dickinson (BD) strengthened its reliance on third-party sterilisation service providers across North America to ensure stable sterilisation capacity for its medical device portfolio amid rising healthcare demand. The company optimized outsourcing partnerships to improve operational efficiency, regulatory compliance, and uninterrupted sterilisation of high-volume single-use products. These efforts supported consistent supply to hospitals and healthcare systems, reflecting broader industry dependence on offsite sterilisation service providers for scalable and compliant sterilisation solutions
• In February 2021, STERIS plc, a leading North American infection prevention and sterilisation services provider, completed the acquisition of Cantel Medical, significantly strengthening its contract sterilisation and healthcare services portfolio across the region. The acquisition expanded its capabilities in medical device sterilisation, endoscopy reprocessing, and outsourced infection prevention solutions, while also enhancing service capacity for medical device manufacturers, pharmaceutical companies, and healthcare facilities requiring validated sterilisation processes

SKU-68916